Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 169 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: epoetin alfa Clear all
Completed Phase 2 Interventional Results available

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

NCT01147666
View directory record Official record
Conditions
End Stage Renal Disease, Anemia
Interventions
Roxadustat, Epoetin Alfa, Placebo
Drug · Other
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 4, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

NCT00597584
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Epoetin alfa or Epoetin beta
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • McGehee, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 4, 2026, 1:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Erythropoetin Neuroprotection for Neonatal Cardiac Surgery

NCT00513240
View directory record Official record
Conditions
Congenital Heart Disease, Hypoplastic Left Heart Syndrome, Transposition of the Great Arteries, Aortic Arch Hypoplasia or Interruption
Interventions
Erythropoetin, Normal saline
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Day to 30 Days
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 4, 2026, 1:27 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

NCT03682536
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Luspatercept, Epoetin alfa
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
25
States / cities
Berkeley, California • San Diego, California • Whittier, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 4, 2026, 1:27 AM EDT
Completed Phase 4 Interventional

Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation

NCT00425126
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Epoetin Alfa
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2010 · Synced Oct 4, 2026, 1:27 AM EDT
Terminated Phase 4 Interventional Results available

Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis

NCT01737879
View directory record Official record
Conditions
Anemia
Interventions
Peginesatide, Epoetin alfa
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Phoenix, Arizona • Tempe, Arizona • Azusa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 4, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)

NCT00002255
View directory record Official record
Conditions
HIV Infections
Interventions
Filgrastim, Epoetin alfa, Zidovudine
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 4, 2026, 1:27 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

NCT00843882
View directory record Official record
Conditions
Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
Interventions
Bone Marrow Biopsy, Epoetin Alfa, Laboratory Biomarker Analysis, Lenalidomide
Procedure · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
507
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 345 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 4, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Results available

Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients

NCT00224003
View directory record Official record
Conditions
Anemia
Interventions
Sodium Ferric Gluconate Complex in Sucrose.
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
2 Years to 16 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2009 · Synced Oct 4, 2026, 1:27 AM EDT
Completed Not applicable Interventional Results available

Effects of Exercise in Combination With Epoetin Alfa

NCT00577096
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Epoetin Alfa, Exercise, Autologous Peripheral Blood Stem Cell Transplantation, Red Blood Cell Transfusion, Thalidomide, Heparin, Low-Molecular-Weight, Platelet Transfusion, Melphalan, Total Therapy II
Drug · Behavioral · Biological
Lead sponsor
University of Arkansas
Other
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 4, 2026, 1:27 AM EDT
Terminated Phase 1 Interventional

Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00005787
View directory record Official record
Conditions
Lymphoma, Neutropenia
Interventions
epoetin alfa, filgrastim, recombinant flt3 ligand, recombinant interleukin-3, sargramostim, in vitro-treated peripheral blood stem cell transplantation
Biological · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
17 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 4, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

NCT01473407
View directory record Official record
Conditions
Chronic Kidney Disease, Chronic Renal Failure
Interventions
Epoetin Hospira, Epogen (Amgen)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
84
States / cities
Montgomery, Alabama • Tempe, Arizona • Alhambra, California + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 4, 2026, 1:27 AM EDT
Recruiting Phase 2 Interventional

Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

NCT05340465
View directory record Official record
Conditions
Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
Interventions
Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection, Oral iron supplements
Drug
Lead sponsor
University of Washington
Other
Eligibility
Up to 3 Days
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 4, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis

NCT01478971
View directory record Official record
Conditions
Chronic Kidney Disease, Anemia
Interventions
Epoetin, Peginesatide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Sacramento, California • San Diego, California • San Jose, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Oct 4, 2026, 1:27 AM EDT
Terminated Not applicable Interventional Results available

The Benefits of a Preoperative Anemia Management Program

NCT01888003
View directory record Official record
Conditions
Anemia, Iron-Deficiency
Interventions
Iron sucrose, Epoetin Alfa, Blood Transfusion
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 4, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional Results available

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

NCT00386152
View directory record Official record
Conditions
Neoplasms, Anemia, Cancer
Interventions
epoetin alfa, darbepoetin alfa
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
76
States / cities
Glendale, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 73 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 4, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

NCT00364832
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
6
States / cities
Los Angeles, California • San Jose, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 4, 2026, 1:27 AM EDT
Active, not recruiting Phase 3 Interventional

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

NCT05949684
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Luspatercept, Epoetin Alfa
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
33
States / cities
Clovis, California • Fountain Valley, California • Los Alamitos, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 4, 2026, 1:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)

NCT01913340
View directory record Official record
Conditions
Hypoxic-ischemic Encephalopathy, Neonatal Encephalopathy, Birth Asphyxia
Interventions
Erythropoietin, Normal saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Minutes to 24 Hours
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Little Rock, Arkansas • Palo Alto, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 4, 2026, 1:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Darbe Administration in Newborns Undergoing Cooling for Encephalopathy

NCT01471015
View directory record Official record
Conditions
Hypoxic Ischemic Encephalopathy
Interventions
Darbepoetin alfa, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
Up to 24 Hours
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Albuquerque, New Mexico • Nashville, Tennessee • Ogden, Utah + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 4, 2026, 1:27 AM EDT
Recruiting Phase 1 Interventional

EVR and EPO for Liver Transplant Tolerance

NCT06832189
View directory record Official record
Conditions
Liver Transplant
Interventions
Everolimus, Epoetin alfa
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 4, 2026, 1:27 AM EDT
Completed Not applicable Interventional

Treatment Program for Anemia in AIDS Patients

NCT00002022
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
R W Johnson Pharmaceutical Research Institute
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 4, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional

Idiopathic Anemia of Aging (IAA)

NCT00104169
View directory record Official record
Conditions
Anemia, Aging
Interventions
Epoetin Alfa
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
70 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2008 · Synced Oct 4, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

NCT03992066
View directory record Official record
Conditions
Anemia Associated With Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa, Epoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
Escondido, California • Denver, Colorado • Fort Lauderdale, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 4, 2026, 1:27 AM EDT